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C-edge loops of arrestin function as a
membrane anchor
Ciara C.M. Lally1, Brian Bauer1, Jana Selent2 & Martha E. Sommer1
G-protein-coupled receptors are membrane proteins that are regulated by a small family of
arrestin proteins. During formation of the arrestin–receptor complex, arrestin ﬁrst interacts
with the phosphorylated receptor C terminus in a pre-complex, which activates arrestin for
tight receptor binding. Currently, little is known about the structure of the pre-complex and its
transition to a high-afﬁnity complex. Here we present molecular dynamics simulations and
site-directed ﬂuorescence experiments on arrestin-1 interactions with rhodopsin, showing
that loops within the C-edge of arrestin function as a membrane anchor. Activation of arrestin
by receptor-attached phosphates is necessary for C-edge engagement of the membrane, and
we show that these interactions are distinct in the pre-complex and high-afﬁnity complex in
regard to their conformation and orientation. Our results expand current knowledge of
C-edge structure and further illuminate the conformational transitions that occur in arrestin
along the pathway to tight receptor binding.
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G
-protein-coupled receptors (GPCRs) comprise a large and
diverse family of membrane proteins in animals. GPCRs
mediate signal transduction in nearly all sensory and
physiological systems and bind a wide range of ligands including
small molecules, peptides and proteins. Binding of agonist
stabilizes an active conformation of the seven transmembrane
helical bundle of the receptor in which the cytoplasmic face is
open to bind G protein1. The G protein is thereby activated and
mediates further cell signalling. The active receptor is also
phosphorylated on multiple sites on its carboxy (C) terminus or
cytoplasmic loops by GPCR kinases (GRK)2, which facilitates
binding of the protein arrestin3.
Remarkably, all GPCRs are regulated by only four different
arrestins. Arrestin-1 and -4 are expressed in photoreceptor cells
in the retina and interact with the visual opsins, and arrestin-2
and -3 (also called b-arrestin 1 and 2, respectively) are expressed
ubiquitously and interact with hundreds of different GPCRs4.
Arrestin binding deactivates receptor signalling by blocking
G-protein binding, and the b-arrestins additionally mediate
receptor endocytosis and trafﬁcking by recruiting elements of the
cellular internalization machinery like clathrin and AP2 to the
receptor5. The b-arrestins interact with hundreds of other
proteins with a wide array of functions, including signalling
kinases and phosphatases, ubiquitin ligases, transcription factors,
cytoskeletal elements and many more6. The b-arrestins mediate
their own signalling networks7,8.
Arrestins are composed of near-symmetric amino (N)- and
C-domains, which resemble two clamshells placed end-to-end
(Fig. 1a,b). A long C-terminal tail (C-tail) interacts extensively
with the N-domain and stabilizes the basal conformation.
Arrestins are activated for receptor binding by the phosphory-
lated C terminus of the receptor, and this initial low-afﬁnity
interaction is termed the pre-complex (Fig. 1c). The phosphory-
lated receptor C terminus displaces the arrestin C-tail,
which results in an B21 rotation of the N- and C-domains
against each other and an increase in ﬂexibility in receptor-
binding loops in the central crest region (see Fig. 1a)9–11.
These conformational changes facilitate tight binding and
transition to the high-afﬁnity complex (Fig. 1c). Arrestins can
also be activated for receptor binding by C-tail truncation, such as
in the naturally occurring splice variant of arrestin-1 called
p44 (Fig. 1b), which lacks the C-tail and thus exists in a pre-active
form that can bind active receptor independent of receptor
phosphorylation12,13.
The ﬁrst crystal structure of arrestin in complex with an active
GPCR was recently published11. A stable complex was achieved
by introducing activating mutations into both binding partners,
mouse arrestin-1 and human opsin, and fusing the N terminus of
arrestin to the C terminus of the receptor via a ﬂexible linker.
Despite these modiﬁcations and the lack of receptor phospho-
rylation, this structure indicates how the conformational changes
associated with arrestin activation facilitate coupling to the active
receptor. Notably, the orientation of arrestin in the crystal
structure of the Ops* arrestin-1 fusion complex suggests that the
344-loop (residues S336–S344 in bovine arrestin-1) within the
distal edge of the C-domain (C-edge, see Fig. 1a) would interact
with the membrane adjacent to the receptor11. Unfortunately, this
loop is not completely resolved, and no membrane is present.
Before the crystal structure, the interaction of the 344-loop with
the membrane was proposed by our group based on site-directed
ﬂuorescence experiments14.
The current study explores the role of the 344-loop and
the C-edge in membrane anchoring of arrestin. Our experimental
approach combines molecular dynamics simulations (in silico)
and site-directed ﬂuorescence spectroscopy (in vitro). For in vitro
experiments, we used bovine arrestin-1 and rhodopsin, which
is the light-sensitive receptor of the rod cell and one of the
best characterized GPCRs. Rhodopsin consists of the protein
opsin and a covalently attached inverse agonist 11-cis-retinal.
Light induces isomerization of the ligand to the agonist
all-trans-retinal, resulting in the active receptor species Metarho-

























Figure 1 | Crystal structure variants of arrestin-1 and schematic of receptor binding equilibrium. (a) Structure of basal arrestin (PDB code 1CF1,
molecule A)25. The N-domain is coloured blue, the C-domain is coloured green and the C-tail is orange. Important loops and regions referred to in this
study are indicated. (b) Comparison of the b- and a-conformers of basal arrestin (1CF1)25, and the C-terminally truncated pre-active arrestin p44 (4J2Q)9.
The interdomain rotation present in p44 is indicated by the rotation axis. (c) Unbound basal arrestin (grey) ﬁrst interacts with the phosphorylated
receptor C terminus in a low-afﬁnity pre-complex. This initial interaction primes arrestin (orange) for the conformational transition required for full
activation (red) and high-afﬁnity coupling to the active receptor.
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advantage that pre-complex and high-afﬁnity complex interac-
tions can be separately observed14,15.
In this study, molecular dynamics simulations indicate that
the C-edge of active arrestin spontaneously interacts with
the membrane. This observation is conﬁrmed using ﬂuorescence
quenching methods, which further suggest distinct orientations
and conformations of the C-edge membrane anchor in the
pre-complex and high-afﬁnity complex. Comparison of simula-
tion and experimental data indicate that the C-edge orientation
identiﬁed in the simulations reﬂects that in the high-afﬁnity
complex and is consistent with the crystal structure of the
arrestin–receptor complex. In addition, we propose a C-edge
conformation for the pre-complex that is congruent with
ﬂuorescence data and based on available crystal structures of
arrestin. All in all, our ﬁndings present a previously unknown
property of arrestin as a membrane-interacting protein.
Results
C-edge of pre-activated arrestin inserts into the membrane. We
ﬁrst investigated how the C-domain of basal arrestin might
interact with a membrane using molecular dynamics simulations
(Fig. 2a). To reduce the system size, we removed both
the N-domain and C-tail and simulated only the isolated
C-domain. The conformational stability of the simulated isolated
C-domain was steady during all simulation runs with an average
RMSD (loops excluded) that did not exceed 1.7 Å compared with
the crystallized C-domain of full-length arrestin (Supplementary
Table 1). We observed no insertion of the arrestin C-domain into
the membrane during 10 replicates with an accumulated
sampling time of 1ms (Table 1, MD1). To explore whether loop
insertion into the membrane is possible at all, we applied
an energetic bias to the arrestin C-domain in the z direction
toward the membrane using metadynamics (three replicates of
100 ns, Table 1, MD2). No insertion occurred, and instead
a deformation of the membrane was observed (Fig. 2b).
Membrane insertion of the 344-loop is not favoured in the
basal state because polar residues E341 and S344 are solvent-
exposed and hydrophobic residues (L338, L342 and T343)
are buried between the 344-loop and the adjacent 197-loop
(residues F197–P202 in bovine arrestin-1; Fig. 2a). Notably, at the
end of one biased simulation from MD2 we observed a sponta-
neous conformational rearrangement of the 344-loop (Fig. 2c),
which resembles that observed in the crystal structure of
pre-activated arrestin p44 (average RMSD of 1.83Å, Fig. 2c part 4
and Supplementary Fig. 1). In contrast to basal arrestin, hydro-
phobic residues of the 344-loop in p44 are solvent-exposed
(Fig. 3a). We next investigated how the C-domain of p44 might
interact with the membrane using unbiased molecular dynamics
simulations (10 replicates of 100 ns, Table 1, MD3). In one of
these simulations, we observed spontaneous insertion of the
C-edge loops into the membrane (Fig. 3b). Speciﬁcally, the
hydrophobic residues L338, L339 and L342 on the 344-loop as
well as residues F197 and M198 on the 197-loop were embedded
within the membrane interior. Apart from these hydrophobic
interactions, we observed polar contacts between the C-edge
loops and the membrane. In particular, S199, D200, S336, S344
and E341 established transient contacts with the membrane,
which ﬂuctuated between polar membrane head groups, solvent
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Figure 2 | Dynamic properties of the C-edge of basal arrestin during biased and unbiased molecular dynamics simulation. (a) All-atom simulation
setup containing the isolated C-domain of basal arrestin (1CF1, molecule D), lipid bilayer (80 80Å) composed of SDPC (1-stearoyl-2-docosahexaenoyl-
sn-glycero-3-phosphocholine), water layer (not shown for simplicity) and solvated to 0.15M NaCl, yielding a system of approximately 80,000 atoms.
Inset: hydrophobic residues L338, L339 and T343 are buried between the 344-loop and the 197-loop, and polar residues E342 and S344 are directed
toward the membrane. (b) Energetic bias of the basal conformation of the 344-loop along the z coordinate using a collective variable of the centre of mass
(COM) of the C-alpha atoms of L338, L339, G340, E341 and L342 (344-loop; three replicates 100 ns, metadynamics). The polar 344-loop is unable to
penetrate the membrane and results instead in a membrane deformation. (c) Conformational rearrangement of the 344-loop from basal (C1) to pre-active
(C2). Unbiased molecular dynamics simulation captured a structural rearrangement of the 344-loop from basal to pre-active during 100 ns (C3).
Superposition (C4) of the crystal structure of pre-active arrestin p44 (yellow, 4J2Q, chain B) with the pre-active conformation obtained in simulation (blue)
yields an average RMSD of 1.83Å. The average RMSD was calculated for residues 335 to 345 and backbone atoms over the last 30 ns of the simulation
MD2 (see also Supplementary Fig. 1).
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negatively charged residues were able to interact at times with
negatively charged lipid head groups via a positively charged
sodium ion. This was observed for D200 (197-loop) during
the process of loop insertion into the membrane before under-
going a conformational change which allowed for frequent
intramolecular interaction with K201 (Supplementary Fig. 2).
Finally, loop insertion into the membrane was conﬁrmed by
biased simulations (three replicates of 100 ns, Table 1, MD4),
which revealed an energetic well for 344-loop at 2.7±1.8 Å from
the polar phosphate atom layer to the centre of mass of the
344-loop (COM344-loop) (Supplementary Fig. 3).
Direct observation of C-edge interactions with the membrane.
We next experimentally probed the proximity of different sites
on arrestin to the membrane when arrestin is in complex with
phosphorylated receptor. Our approach was based on quenching
of site-speciﬁcally placed ﬂuorophores on arrestin by spin labels
located at different levels within the membrane (see Supple-
mentary Note 1). First, 16 individual sites within arrestin-1 were
mutated to cysteine, and the ﬂuorophore bimane was attached.
Next, native rod outer segment membranes (ROS) containing
phosphorylated rhodopsin (Rho-P) were enriched with fatty acids
labelled with nitroxide spin labels (Supplementary Table 2). For
N-tempoyl-palmitamide, the spin label is localized within the
polar head-group region of the membrane, and for 5-doxyl-
stearic acid, the spin label is localized within the hydrophobic
interior of the membrane near carbon 5 on the fatty acid chain of
the phospholipid. As a control, ROS membranes were also enri-
ched with analogous fatty acids lacking spin label, speciﬁcally
methyl-palmitate or stearic acid. Robust binding of all labelled
arrestin mutants to the enriched ROS membranes was veriﬁed by
centrifugal pull-down analysis (Supplementary Fig. 4). Our
experimental conditions ensured comparable binding of arrestin
mutants to both dark-state Rho-P and light-activated Rho*-P
(see Supplementary Note 2).
Table 1 | Details of molecular dynamics simulations.
Experiment ID Simulation description Simulation length
MD1 C-domain of basal arrestin (1CF1, molecule D)
Unbiased simulation
10 100ms
MD2 C-domain of basal arrestin (1CF1, molecule D)
Biased simulation well-tempered metadynamics (hills height 2, biasfactor 15)
3 100 ms
MD3 C-terminal of the pre-activated arrestin (4J2Q, chain B)
Unbiased simulation
10 100ms
MD4 C-terminal of the pre-activated arrestin (4J2Q, chain B)
Biased simulation well-tempered metadynamics (hills height 2, biasfactor 15)
3 100 ms







































Figure 3 | C-edge of pre-active arrestin p44 spontaneously inserts into membrane bilayer. (a) All-atom simulation setup containing the isolated
C-domain of the pre-active arrestin p44 (4J2Q, chain B), lipid bilayer (8080Å) composed of SDPC (1-stearoyl-2-docosahexaenoyl-sn-glycero-3-
phosphocholine), water layer (not shown for simplicity) and solvated to 0.15M NaCl yielding a system of approximately 80,000 atoms. Inset:
conformation of the 344-loop in pre-active arrestin p44 directs hydrophobic residues L338, L339 and L342 toward the lipid bilayer. (b) In an accumulated
time of 1ms (10 100 ns) of unbiased molecular dynamics simulation (MD 3), we observed one spontaneous penetration of the 344-loop into the lipid
bilayer. After 40 ns simulation time, hydrophobic residues of the 344-loop (L338, L339, L342) as well as the 197-loop (F197 and M198) dip into the
hydrophobic region of the lipid bilayer.
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The ﬂuorescence of each arrestin mutant was measured in the
presence of the different enriched ROS membranes (Fig. 4).
Quenching efﬁciency was evaluated by comparing the ﬂuores-
cence in the presence or absence of spin labels for both the
dark-state pre-complex and the light-activated high-afﬁnity
complex (Fig. 5 and Table 2). Note that this procedure allows
the exclusion of possible quenching of bimane ﬂuorophores
on arrestin by receptor tryptophan and tyrosine residues
(see Supplementary Note 3). Quenching was primarily localized
to the 344-loop and the 197-loop within the C-edge, as well as the
160-loop (site 161) and loops within the central crest region,
namely the middle loop (site 139) and the C-loop (site 251;
see Fig. 1a). No quenching of arrestin labelled on the 344-loop
was observed using a large excess of nonphosphorylated
ROS membranes enriched with spin-labelled fatty acids
(Supplementary Fig. 5), indicating that membrane engagement
by arrestin is dependent on the presence of phosphorylated
receptor.
In the pre-complex, relative deep membrane insertion
was implied by signiﬁcant quenching at sites 342 (30%) and
339 (15%) by 5-doxyl-stearate (Fig. 5 and Table 2). Site 342 was
also quenched to a lesser extent by N-tempoyl-palmitamide
Dark-state pre-complex Light-activated high-affinity complex
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Figure 4 | Example ﬂuorescence spectra of bimane-labelled arrestin mutants in the presence of enriched ROS-P membranes. The ﬂuorescence
(lex: 400 nm) of each bimane-labelled arrestin mutant (1 mM) was measured in the unbound state (grey spectra) or when bound to ROS-P (4 mM) control
membranes (black spectra). The ﬂuorescence in the presence of fatty-acid enriched ROS-P membranes is also shown: red, methyl palmitate; blue,
N-tempoyl-palmitamide; orange, stearic acid; green, 5-doxyl-stearic acid. Note that ﬂuorophores attached to sites on the membrane anchor (197, 339, 342,
344) display a spectral blue-shift upon complex formation with ROS-P (both dark-state and light-activated), indicating localization in a hydrophobic
environment. Fluorescence spectra are normalized such that the ﬂuorescence intensity of each mutant in the unbound state equals 1.
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(11%), along with sites 334 and 344 (13 and 17%, respectively),
indicating their proximity to the polar phospholipid head-group
region of the membrane. On transition to the high-afﬁnity
complex, changes in the pattern of quenching implied a shift
of the C-edge closer to the head-group region. Site 342 became
more accessible to N-tempoyl-palmitamide (31% quenching)
as compared with the 5-doxyl-stearic acid (22%). Likewise,
neighbouring sites 339 and 344 were more quenched by
N-tempoyl-palmitamide (27% and 30%, respectively) than
5-doxyl-stearic acid (18% and 19%, respectively). We additionally
observed strong quenching at site 197 on the 197-loop by
N-tempoyl-palmitamide (23%) and 5-doxyl-stearic acid (23%),
but only in the light-induced high-afﬁnity complex. This result
conﬁrms the role of the 197-loop in membrane engagement as
suggested by the MD simulations (Fig. 3b) and further indicates
that, in the high-afﬁnity complex, the C-domain of arrestin
adopts a similar orientation as seen in the simulations.
Notably, arrestin mutants F197B, L339B, L342B and S344B
displayed signiﬁcant blue-shifts in ﬂuorescence (Z10 nm) when
arrestin bound to the ROS membranes (Fig. 4 and Table 2). These
wavelength shifts indicate translocation of the bimane ﬂuor-
ophore from a polar to hydrophobic environment and are
consistent with the observed quenching by 5-doxyl stearic acid at
these sites. Importantly, wavelength shifts are independent of
changes in ﬂuorescence intensity and therefore conﬁrm the
membrane insertion of these sites on the C-edge. A previous
EPR study of arrestin-1 indicated that spin label at site 344 is
modestly immobilized in both the dark-state pre-complex and
light-activated high-afﬁnity complex16, which is consistent with
this site embedding in the highly ﬂuid ROS phospholipid
membrane17,18. In contrast, spin label at site 72 on the ﬁnger
loop showed a considerable loss of mobility in the dark-state
pre-complex and was nearly immobilized in complex with light-
activated Rho*-P (ref. 16). This result is due to the embedding of
site 72 within the cytoplasmic crevice of the active receptor11,19
and is complementary to the signiﬁcant blue-shift in ﬂuorescence
displayed by arrestin I72B upon binding Rho*-P (refs 11,19,20;
see also Fig. 4 and Table 2).
Curiously, ‘negative quenching’ by 5-doxyl-stearic acid
was observed for arrestin mutants N271B, T334B and S344B in
the pre-complex, arising from the fact that the ﬂuorescence in
the presence of unlabelled stearic acid was lower than in the
presence of the nitroxide-containing 5-doxyl-stearic acid.
Carboxyl groups are known to quench ﬂuorescence21, and we
hypothesize that this negative quenching effect is due to the
carboxyl groups of the labelled and unlabelled stearic acid not
being equivalent in their ability to quench bimane ﬂuorescence.
The inﬂuence of nearby carboxyl groups on bimane probes
at sites 271, 334 and 344 is supported by the observed accessi-
bility of these sites to N-tempoyl-palmitamide (8%, 13% and
17% quenching, respectively).
Close proximity of other loops to the membrane surface.
Quenching by N-tempoyl-palmitamide was observed at site
72 (10%) on the arrestin ﬁnger loop in the high-afﬁnity complex.
In the crystal structure of the Ops*–arrestin-1 fusion complex11
and the earlier crystal structure of Ops* bound to a peptide
analogue of the ﬁnger loop19, site 72 is located near the base of
the cytoplasmic crevice of the receptor. This placement
presumably makes the bimane ﬂuorophore accessible to the
spin label of N-tempoyl-palmitamide within the head-group
region of the membrane. In contrast, no quenching by
N-tempoyl-palmitamide was observed at site 75 in the high-
afﬁnity complex, which is consistent with the deeper placement of
site 75 within the receptor crevice11,19.
Quenching by N-tempoyl-palmitamide was also observed at
site 251 on the arrestin C-loop in both the pre-complex (20%)
and the high-afﬁnity complex (23%). The proximity of site 251 to
the membrane surface in the high-afﬁnity complex is suggested
by the crystal structure of the Ops*–arrestin-1 fusion complex,
where the C-loop of arrestin is seen to be close to the cytoplasmic
end of transmembrane helix 3 (ref. 11). Curiously, there was
quenching of the bimane at site 251 by 5-doxyl-stearic acid
in both the pre-complex (12%) and the high-afﬁnity complex
(18%), even though arrestin S251B displayed only a minimal
blue-shift in ﬂuorescence when receptor-bound (3 to 5 nm, Fig. 4
and Table 2). Likewise, the bimane at site 139 was quenched by
5-doxyl-stearic acid in the pre-complex (14%) even though no
blue-shift was observed (Table 2). In the crystal structure of the
Ops*–arrestin-1 complex, the alpha carbons of both sites 251 and
139 are 418Å away from the putative position of C5 of the
phospholipid acyl chain (see Fig. 6 below and the ‘Methods’
section for details on how membrane position was calculated for
the crystal structure). Hence it is not immediately obvious how
these sites could be accessible to 5-doxyl-stearate. The observed
quenching of sites on the C- and middle loops by 5-doxyl-stearate
might mean that these loops adopt signiﬁcantly different poses
than seen in the crystal structure. Alternatively, the quenching
might be artefactual and due to secondary changes at these sites
arising from the negatively charged head-group of the 5-doxyl-
stearate.
In the crystal structure of the Ops*–arrestin-1 fusion
complex11, the 160-loop bends back over the arrestin
N-domain, which allows it to interact with the cytoplasmic
end of transmembrane helix 6. Although the crystal structure
suggests 415Å between the putative membrane surface and
the 160-loop, we measured signiﬁcant quenching at site 161 by
N-tempoyl-palmitamide in both the pre-complex and high-
afﬁnity complex (21% and 19%, respectively). Consistently,
‘negative quenching’ was measured at nearby site 159 by
5-doxyl-stearate, which indicates close proximity of this site
and the membrane surface (see discussion above). These results
suggest the ﬂexible 160-loop might be able to adopt other







































Figure 5 | Summary of ﬂuorescence quenching experiments. The
measured quenching efﬁciencies at each site on arrestin in the dark-state
pre-complex and the light-activated high-afﬁnity complex (see Table 2) is
indicated by a colour spectrum ranging from 0 to 30% (spheres located at
Ca). Black indicates instances where ﬂuorescence was enhanced by the
presence of spin-labelled fatty acid (that is, negative quenching). Arrestin
models are based on the structure of arrestin-1 reported by Hirsch et al.25
(1CF1, molecule A), and the C-tail is omitted for clarity.
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conformations than seen in the crystal structure of the
Ops*–arrestin-1 fusion complex, speciﬁcally those that
allow sites 159 and 161 close contact with the membrane
surface. Interestingly, negative-stain electron microscopy of
GPCR–b-arrestin complexes, in which the helical core of the
receptor is not engaged by the arrestin ﬁnger loop, reveals
orientations in which the tip of the N-domain is positioned
close to the receptor22,23. Such an orientation would put the
160-loop within close proximity to the quenching group of
N-tempoyl-palmitamide.
Comparison of MD and experimental data. To compare
molecular dynamics data with quenching results in more detail,
we calculated distance values from the simulations that are
expected to correspond to quenching efﬁciencies of N-tempoyl-
palmitamide and 5-doxyl-stearic acid. DistP relates to the
distances from the alpha carbons (Ca) of selected sites on arrestin
to the level of the phosphate atoms (P) within the membrane.
DistC5 corresponds to the distance of from Ca of selected sites on
arrestin to the level of the carbon at position ﬁve on the second
aliphatic chain (C5) of the phospholipids. We compared the DistP
and DistC5 averaged over the simulation (MD3) to the ﬂuores-
cence quenching efﬁciencies observed for the high-afﬁnity
complex (Supplementary Fig. 6). MD simulations suggest that
residues 197, 339 and 342 are close (o5Å) to the phosphate atom
layer, which is in line with N-tempoyl-palmitamide quenching
data. One exception is site 344, for which the averaged simulation
data predicted a position further away from the phosphate layer
(48Å) than that determined by ﬂuorescence experiments.
A similar discrepancy is seen for residue 344 when comparing the
MD-derived DistC5 to the quenching efﬁciency of 5-doxyl-stearic
acid. Differences between simulation and quenching data of the
C-edge can be assigned to the fact that the isolated C-domain was
simulated in the absence of the receptor, which allowed for more
ﬂuctuation. In contrast, quenching experiments were carried out
in the presence of the receptor, which couples to arrestin and
thereby restricts movement of the whole arrestin including the
C-edge. Furthermore, the MD-derived distances were measured
from Ca, while quenching data derived from a bimane probe
attached to a cysteine residue, which affords a large degree of
rotational freedom many angstrom units away from Ca. Despite
these differences, comparison indicates that the MD simulation
mirrors the position of the C-edge in arrestin-1 bound to phos-
phorylated Meta II (that is, high-afﬁnity complex).
Ultimately, we selected one frame out of the pool of simulated
C-domain positions and conformations based on the best ﬁt
to both the C-domain of arrestin and the membrane plane
(OPM-based) in the crystallized Ops*–arrestin-1 complex
(see the ‘Methods’ section for more details). The selected frame
















Finger loop I72B 0.94±0.16 (2) 0.87±0.12 (2) 0.85±0.10 (2) 2.3 0.90±0.15 (2) 0.94±0.16 (2) 4.4  5
M75B 0.89±0.08 (2) 0.86±0.04 (2) 0.95±0 (2)  10.5 0.86±0 (2) 0.82±0.01 (2) 4.6
Near a-helix V94B 1.05±0 (2) 1.02±0 (2) 1.08±0.03 (2) 5.9 1.13±0.03 (2) 1.09±0.04 (2) 3.5
Middle loop V139B 0.86±0.02 (2) 0.87±0.05 (2) 0.87±0 (2) 0 0.84±0 (2) 0.72 ±0.02 (2) 14.3
160-loop V159B 1.08±0.05 (3) 1.15±0.03 (3) 1.09±0.10 (3) 5.2 1.04±0.10 (3) 1.19±0.02 (3)  14.4
E161B 1.3±0.05 (2) 1.4±0.2 (2) 1.1±0.13 (2) 21.4 1.3±0.25 (2) 1.25±0.12 (2) 3.8
K163B 0.92±0.10 (2) 0.98±0.06 (2) 0.94±0.11 (2) 4.1 0.90±0.09 (2) 0.87±0.05 (2) 3.3
C-domain
197-loop F197B 0.89±0.03 (2) 0.94±0(2) 0.88±0.06 (2) 6.4 0.88±0.05 (2) 0.81±0.07 (2) 7.9
230-loop S229B 1.16±0.04 (2) 1.02±0.05 (2) 1.10 ±0 (2)  7.8 1.03±0.01 (2) 0.95±0.03 (2) 7.8
T230B 1.05±0.17 (3) 1.08±0.14 (3) 1.01±0.15 (3) 6.5 0.96±0.17 (3) 0.95±0.16 (3) 1.0
C-loop S251B 2.15±0.5 (3) 1.83 ±0.31 (3) 1.46±0.10 (3) 20.2 1.79±0.22 (3) 1.58±0.09 (3) 11.7  3
270-loop N271B 1.04±0.03 (3) 1.06±0.04 (3) 0.98±0.05 (3) 7.5 0.89±0.11 (3) 1.05±0.14 (3)  18.0
344-loop T334B 0.70±0.02 (3) 0.64±0 (3) 0.56±0 (3) 12.5 0.58 ±0.08 (3) 0.66±0.05 (3)  13.8
L339B 0.99±0.02 (2) 1.22±0.09 (2) 1.17±0.07(2) 4.1 0.93±0 (2) 0.79±0.04 (2) 15.0  5
L342B 1.01±0.2 (2) 1.13 ±0.26 (2) 1.01±0.23 (2) 10.6 0.98±0.21 (2) 0.69±0.08 (2) 29.6 8
S344B 0.5±0.07 (2) 0.58±0.12 (2) 0.48±0.05 (2) 17.2 0.46±0.02 (2) 0.51±0.04 (2)  10.9  3
Light-activated high-afﬁnity complex
N-domain
Finger loop I72B 1.66 ±0.13 (2) 1.69 ±0.07 (2) 1.52 ±0.12 (2) 10.1 1.77 ±0.21 (2) 1.86±0.24 (2) 5.1  27
M75B 0.93±0.07 (2) 0.95±0.02 (2) 0.97±0.03 (2)  2.1 0.97±0.02 (2) 0.95±0.05 (2) 2.1 6
Near a-helix V94B 1.08±0 (2) 1.05±0 (2) 1.12±0.04 (2) 6.7 1.23±0.02 (2) 1.18±0.04 (2) 4.1
Middle loop V139B 1.29±0.02 (2) 1.15±0.02 (2) 1.12±0.01 (2) 2.6 1.23±0 (2) 1.18±0.02 (2) 4.1
160-loop V159B 1.19±0.06 (3) 1.30±0.04 (3) 1.18±0.11 (3) 9.2 1.19±0.11 (3) 1.38±0.05 (3)  16.0
E161B 1.3±0.08 (2) 1.42±0.15 (2) 1.15±0.14 (2) 19.0 1.31±0.26 (2) 1.31±0.12 (2) 0
K163B 0.95±0.10 (2) 1.01±0.05 (2) 0.94±0.11 (2) 6.9 0.97±0.09 (2) 0.96±0.05 (2) 1.0
C-domain
197-loop F197B 1.07±0.04 (2) 1.13±0.02 (2) 0.87±0.08 (2) 23.0 1.11±0.07 (2) 0.85±0.11 (2) 23.4  11
230-loop S229B 1.28±0.03 (2) 1.20±0.03 (2) 1.19±0.02 (2) 0.83 1.18±0.05 (2) 1.25±0.06 (2) 5.9
T230B 1.07±0.14 (3) 1.06±0.10 (3) 0.96±0.14 (3) 9.4 1.03±0.14 (3) 0.98±0.15 (3) 4.8  3
C-loop S251B 2.8±0.5 (3) 2.48±0.29 (3) 1.90±0.16 (3) 23.4 2.39±0.2 (3) 1.95±0.07 (3) 18.4  5
270-loop N271B 1.01±0.03 (3) 1.03±0 (3) 0.95±0.06 (3) 7.8 0.98±0.13 (3) 1.13±0.11 (3)  15.3
344-loop T334B 0.95±0.04 (3) 1.05±0.06 (3) 0.92±0 (3) 12.4 0.95±0.04 (3) 0.93±0.04 (3) 2.1
L339B 1.11±0.11 (2) 1.37±0.08 (2) 1.0±0.03 (2) 27.0 1.16±0.11 (2) 0.95±0.08 (2) 18.1  10
L342B 1.01±0.23 (2) 1.06±0.21 (2) 0.73±0.16 (2) 31.1 1.03±0.25 (2) 0.80±0.12 (2) 22.3  10
S344B 0.78±0.04 (2) 0.84±0.02 (2) 0.59±0 (2) 29.8 0.78±0.08 (2) 0.63±0.05 (2) 19.2  10
Fluorescence intensities are normalized to the ﬂuorescence of 1 mM unbound arrestin (see ‘Methods’ section for more details). Mean±s.e. is reported. Numbers in parentheses indicate number of
independent measurements. Quenching efﬁciencies (bold) are reported as a percentage, and the colour scheme follows the template shown in Fig. 5 (quenching levels: blue¼ little to none,
green¼moderate, red¼ signiﬁcant). Negative wavelength shifts (bold) indicate shifts to lower values.
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reﬂects the positioning and conformation of the crystallized
C-domain with the advantage of having the C-edge loops
resolved. Figure 6 presents a superposition of the sampled C-edge
conformation derived from our MD simulation (MD3) to the
crystallized Ops*–arrestin-1 complex. The selected simulation
frame shows that residues 197, 339, 342 and 344 are within 5 to
10Å of the C5. Consistently, these sites were quenched by
5-doxyl-stearic acid (18 to 23%). The simulated structure also
indicates that residues 229, 230, 271 and 334 are 415Å away,
which ﬁts well to the lack of 5-doxyl-stearate-induced quenching
at these sites. Furthermore, simulation data suggest that residues
197, 339, 342 and 344 are in close vicinity (o4Å) to the
phosphate (P), which is mirrored by high ﬂuorescence quenching
(423%) at these sites by N-tempoyl-palmitamide. Sites 334 and
230 showed moderate quenching (B10%) with MD-estimated
distances around 10Å. Both MD and ﬂuorescence quenching
indicated a large distance between the phosphate layer and sites
229 and 271. In summary, this comparative analysis indicates that
the crystal structure of the Ops*–arrestin-1 fusion complex most
likely represents the high-afﬁnity complex.
Membrane anchor structure in the pre-complex. Comparison
of simulation and ﬂuorescence data suggest that the C-edge
orientation and conformation obtained by MD using the p44
structure is similar to the high-afﬁnity complex (see above).
Fluorescence experiments indicate that, in the pre-complex, sites
342 and 339 are more deeply inserted than in the high-afﬁnity
complex, and site 197 is not engaged in the pre-complex
(see Fig. 5 and Table 2). Thus we anticipate that, in the
pre-complex, the conformation of the C-edge and its orientation
with respect to the membrane differ from that seen in the
MD simulation. The 344-loop is highly ﬂexible and can adopt
multiple conformations, as seen in the different crystal structures
of basal and pre-active arrestin-1 (see Fig. 1b)9,24–27. For example,
in the crystallographic ‘a-conformer’ seen in the arrestin-1 crystal
structure reported by Hirsch et al. (molecules A and C in
PDB structure 1CF1), the 344-loop is extended such that the
aliphatic residues L338, L339 and L342 are exposed25. This
orientation stands in contrast to that seen in the ‘b-conformer’
(molecules B and D in PDB structure 1CF1), where the side
chains of these residues are buried between the b-sheets of the
C-edge (see Fig. 2a). Intriguingly, positioning the C-domain of
the a-conformer at a similar angle to the membrane as in the
high-afﬁnity complex would allow side chains of residues 342 and
339 access to the hydrophobic interior of the membrane while
excluding site 197 (Fig. 7). Such arrangement would be consistent
with quenching results for the pre-complex.
Discussion
This study describes a previously unknown function of the
C-domain of arrestin-1. Membrane anchoring is an ability
arrestin shares with the other major interaction partners of
GPCRs, although arrestin achieves this without the lipid anchors
present in G proteins and GRKs. Here we identiﬁed the 344-loop
and the 197-loop as comprising the C-edge membrane anchor.








































Figure 6 | Comparison of simulation and ﬂuorescence data with the crystal structure of the Ops*–arrestin-1 complex. (Left) Superimposition of the
Ops*–arrestin-1 fusion complex crystal structure (green, PDB ID: 4ZWJ) to a sampled C-edge conformation during MD simulation (grey). Coloured
horizontal lines indicate the positions for individual lipid atoms: grey lines: C=O based on the OPM database, red line: carbon 5 (C5) based on MD, brown
line: phosphate atoms based on MD. (Right) Distance and ﬂuorescence maps, derived from all-atom simulation and site-directed ﬂuorescence
experiments, respectively. Distances are depicted for a sampled C-edge conformation which was selected based on the best ﬁt to the arrestin in the
Ops*–arrestin-1 fusion complex structure with a RMSDC-domain_arrestin of 1.54Å (calculated over all backbone atoms). The colour spectrum (0 to 20Å)
corresponds to the distance of the C-alpha carbon (VdW representation) of residues on arrestin to phosphate atoms (relates to the position of the spin
label in N-tempoyl-palmitamide) and C5 atoms (relates to the position of the spin label in 5-doxyl stearic acid). The quenching data are coloured according
to the degree of quenching (0 to 30%). The white asterisk indicates instances of negative quenching (see text for details).
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with one another, and together they corroborate the membrane
engagement of the arrestin C-edge suggested by the crystal
structure of arrestin-1 bound to active opsin11. Our ﬂuorescence
data further suggest a distinct membrane anchor conformation
and orientation for the pre-complex, for which very little
structural information exists. The membrane anchor is a key
element involved in stabilizing the ﬂexible arrestin-receptor
complex along the path to tight binding. On one hand, the
membrane anchor is a general binding element that bestows
versatility on arrestin binding, since every GPCR resides in
a membrane. On the other hand, the membrane anchor supports
speciﬁcity in binding, since the C-edge is activated for membrane
engagement when arrestin interacts with the phosphorylated
receptor C terminus.
The C-edge membrane anchor of arrestin is markedly similar
to the C2 family of membrane binding domains. These domains
consist of a concave eight-stranded antiparallel b-sandwich,
which interacts with the membrane using the interconnecting
loops on one edge of the sandwich28,29. Importantly, the C-edge
membrane anchor of arrestin-1 we describe here shares many of
these attributes, including an abundance of basic charges within
the concave surface of the b-sandwich (e.g., K235, K236, K238,
K267, K332, K333), which might provide an electrostatic
attractive force to bring the C-domain to the membrane.
Previous studies by us and others have indicated that negatively
charged phospholipids are necessary for arrestin-1 to bind light-
activated phosphorylated rhodopsin30,31. Remarkably, acidic
phospholipids are ﬂipped to the outer membrane leaﬂet by
rhodopsin activation32,33. It is interesting to consider how
increased electronegativity of the membrane surface induced by
rhodopsin activation might recruit the positively-charged arrestin
C-edge to the membrane.
Membrane anchoring is an attribute arrestin shares with other
members of the arrestin clan, whose members all share the basic
arrestin fold of two near-symmetric concave beta-sandwich
domains34. Members include the Vps26 proteins, which are
part of the retromer complex involved in endosomal membrane
trafﬁcking, and the a-arrestins (also called ARRDC), which are
the oldest members of the clan and are believed to function as
scaffolding proteins to mediate ubiquitination and endocytic
sorting of GPCRs and other receptors at the membrane35. All
members of the arrestin clan have the capacity to interact with the
membrane, although they share very little sequence identity
(11–15%; ref. 35) and appear to use different mechanisms of
membrane interaction36,37.
Intriguingly, the C-edge is preserved to different extents in the
four arrestins. Although the 197-loop is preserved in all members,
the 344-loop is lacking in arrestin-3 (b-arrestin 2) and the short
splice variant of arrestin-2 (b-arrestin 1). The longer splice
variant of arrestin-2 contains an eight-amino acid insert
(334LLGDLASS341) in the 344-loop38, which is nearly identical
to that in arrestin-1. Remarkably, this insert has been observed by
X-ray protein crystallography to bind clathrin, and this
interaction is sufﬁcient to mediate recruitment of active
b2 adrenergic receptors to clathrin-coated pits in the absence
of the principal clathrin binding motif located in the C-tail39.
Mutagenesis analysis deﬁned the secondary clathrin-binding
motif as (L/I)2GXL, which contains the three membrane-
interacting leucine residues (L338, L339 and L342 in arrestin-1)
we have identiﬁed in this study. Interestingly, in the crystal
structure of arrestin-2 bound to clathrin39, the 344-loop bears
a similar outward orientation of leucine residues as seen in the
pre-activated arrestin-1 (p44)9 (Supplementary Fig. 7). It is likely
that the long variant of arrestin-2 can interact with the membrane
similarly as we have observed with arrestin-1. Supposedly
membrane engagement and clathrin binding are mutually
exclusive, although one can imagine that sequential engagement
of the membrane and clathrin by the 344-loop is conducive to
endocytosis.
Regarding the other arrestin variants that lack the 344-loop,
it is possible that the 197-loop is sufﬁcient to act as a membrane
anchor when arrestin engages an active GPCR, or that the
shorter version of the 344-loop engages the membrane surface.
Interestingly, arrestin-3 has an outwardfacing arginine residue
at site 332 (also present in the shorter version of arrestin-2),
which supposedly could interact with phospholipid head-groups
of the membrane. Clearly, the longer version of the 344-loop
is not absolutely necessary for the two b-arrestins to interact
with GPCRs. No signiﬁcant difference in binding of the long
and short variants of arrestin-2 to the b2 adrenergic and
m2 muscarinic cholinergic receptors was observed in vitro40,
although these variants are expressed in different tissues and
cell types, suggesting they might interact with different sets of
GPCRs38,39. It is intriguing to consider that the longer version
of the 344-loop serves as variable binding element. In the
visual arrestins, this loop can penetrate the membrane to stabilize
both the pre-complex and high-afﬁnity complex, while in
the longer version of arrestin-2 this loop can additionally
couple to clathrin. The functional role of the C-edge in the
b-arrestins for binding membrane and mediating receptor
internalization remains to be clariﬁed.
The fact that the C-edge of arrestin-1 is activated
for membrane binding when arrestin interacts with the
phosphorylated rhodopsin C-terminus suggests the membrane
anchor plays a role in the formation and stabilization of the
pre-complex. The primary contact between receptor and arrestin
is the binding of the phosphorylated receptor C-terminus























Figure 7 | Different conformational states of the C-edge. (a) Superposition of sampled MD frame obtained based on the best ﬁtting to the crystallized
Ops*arrestin-1 complex (PDB ID: 4ZWJ) to the ‘a-conformer’ seen in the crystal structure of arrestin-1 reported by Hirsch et al. (PDB ID: 1CF1, molecule A).
(b) Sampled MD frame alone. (c) Crystallized ‘a-conformer’ alone. The averaged layer of phosphate atoms (P) and carbon 5 (C5) of lipids are
simulation-based coordinates and are indicated by tan and red lines, respectively.
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the N-domain. The receptor C terminus is long and ﬂexible, and
an arrestin tethered solely to the receptor C terminus
would be expected to be highly mobile. The anchoring of the
arrestin C-edge in the membrane would restrict this mobility,
thereby bringing the receptor binding elements of arrestin
(for example, ﬁnger loop) into closer proximity of the receptor
and facilitating transition to the high-afﬁnity complex. Intrigu-
ingly, electron microscopy (EM) of arrestin-2 bound to a GPCR
(chimera of b2 adrenergic and V2 vasopressin receptor) captured
a ‘hanging’ binding mode of arrestin23. Considering that the
receptor used in these studies was solubilized in a neutral
detergent and not a phospholipid membrane, this mode of
interaction could represent the pre-complex without the beneﬁt
of membrane anchoring.
A subsequent EM study has recently reported the existence
of ‘megaplexes’ composed of a GPCR bound simultaneously to
G protein and b-arrestin, which give rise to sustained signalling
from internalized receptors in endosomes22. In these complexes,
the G protein is coupled to the helical core of the receptor, and
arrestin is bound nearby, supposedly tethered by the
phosphorylated receptor C-terminus. The orientation of arrestin
in this complex suggests deep insertion of the C-edge into the
theoretical membrane plane22, which would be expected to
stabilize arrestin association within the megaplex in the absence
of binding the receptor core. Notably, these EM-visualized
complexes of receptor-bound b-arrestin, in which the arrestin
ﬁnger loop does not engage the receptor core22,23, could represent
different possible pre-complex formations.
Our experimental ﬁndings allow us to make predictions
regarding the structure of arrestin in the pre-complex and
the conformational transitions that occur during formation of
the high-afﬁnity complex. We predict that the 344-loop adopts
an extended, a-conformer-like conformation in the pre-complex,
which allows it to deeply penetrate the hydrophobic interior
of the membrane. We further expect that the C-domain is
not signiﬁcantly rotated in the pre-complex as compared
with the basal state, which excludes the 197-loop from
membrane interaction. On transition to the high-afﬁnity
complex, arrestin is fully activated and the C-domain rotates
21, thereby allowing the 197-loop to engage the membrane.
We further predict that the 344-loop adopts a folded conforma-
tion similar to that seen in the crystallized p44 structure,
which favours a more shallow interaction with the membrane.
This mode of binding was captured in our MD simulations
using an isolated C-domain of pre-active p44, and we anticipate
that this interaction signiﬁcantly stabilizes the high-afﬁnity
complex. Note that the different membrane anchor orientations
for the pre-complex and high-afﬁnity complex, which we
predict based on our ﬂuorescence data, is corroborated by
a recent alanine scan mutagenesis study of arrestin-1 binding to
inactive and active phosphorylated rhodopsin41.
In summary, our study redeﬁnes arrestin as both
a GPCR-binding and membrane-binding protein. These binding
behaviours are cooperative and dependent on one another, since
arrestin cannot engage the membrane in the absence of
phosphorylated receptor, and arrestin cannot bind receptors
without the presence of membrane (or at least phospholipids).
Our ﬁndings open new avenues of research to understand the
role of the membrane in arrestin activation and receptor binding,
and how these membrane interactions inﬂuence the different
functions of arrestin in the cell.
Methods
Unbiased molecular dynamics simulation. To study the dynamic properties
of the C-edge with sufﬁcient sampling, we focused on the isolated C-domain.
The C-domain (residues 182 to 360) of the basal arrestin (1CF1, molecule D)
and the pre-activated arrestin (4J2Q, chain B) were retrieved from the
Protein Databank9,25. The ends were capped using standard group patching
(NTER and CTER). The charmm-gui membrane builder42 was used to place
the C-edge of the C-domain approximately 3Å below the membrane. The
generated membrane patch consisted of pure 1-stearoyl-2-docosahexaenoyl-sn-
glyerco-3-phosphocholine (SDPC) with a size of 80 80Å2. The system
was solvated and ionized to 0.15M sodium chloride yielding a total number of
atoms of B78,000.
Molecular dynamics simulations were performed using ACEMD43 using the
following protocol: In a ﬁrst stage, each system was submitted to a minimization
procedure for 3,000 steps. In a second stage, the system was equilibrated using the
NPT ensemble with a target pressure equal to 1.01325 bar, a time-step of 2 fs and
using the RATTLE algorithm for the hydrogen atoms. In this stage, the harmonic
constraints applied to the heavy atoms of the protein and ligand were progressively
reduced from an initial value of 10 kcalmol 1 Å 1 until an elastic constant force
equal to 0 kcalmol 1 and the temperature was increased to 300 K. All the
simulations were conducted using the same non-bonded interaction parameters,
with a cut-off of 9 Å, a smooth switching function of 7.5 Å and the non-bonded
pair list set to 9Å. For the long-range electrostatics, we used the PME
methodology with a grid spacing of 1Å. In a third stage, production phases
were performed using the NVT ensemble with aforementioned parameters
but a time-step of 4 fs, and a hydrogen scaling factor of 4. This time-step is
possible due to the implementation of the hydrogen mass repartitioning
scheme in the ACEMD code44. A summary of all unbiased simulations is
found in Table 1.
To elect a MD frame that best ﬁt the Ops*P–arrestin-1 crystal structure,
backbone atoms of the C-domains of all simulation frames for MD3 were
ﬁrst aligned to the C-domain of the crystallized Ops*–arrestin-1 complex
(PDB ID: 4ZWJ), which was retrieved from the OPM database45. The OPM
structure provides spatial arrangements of membrane proteins with respect to the
hydrocarbon core of the lipid bilayer, provided as dummy atoms that describe
the position of the carbonyl lipid (C¼O) layer. In a second step, the C-domain-
aligned frame with the best ﬁt to the OPM-deﬁned C¼O layer was selected
(see Fig. 6).
Biased molecular dynamics simulation. Metadynamics is a biased dynamics
technique widely used to improve sampling for free energy calculations over
a set of multidimensional reaction coordinates, which would not be sampled
exhaustively with normal unbiased simulations46. It is implemented in the
molecular dynamics code ACEMD using the PLUMED plugin interface47. We used
metadynamics to estimate the energetic barrier that the C-domain requires to enter
the membrane. For this, we positioned the C-domain (1CF1, molecule D) below
the lipid bilayer (80 80Å) composed of SDPC (1-stearoyl-2-docosahexaenoyl-sn-
glycero-3-phosphocholine). The system was solvated and ionized to 0.15M NaCl,
yielding a system ofB80,000 atoms. We used as reaction coordinate the z position
of the centre of mass (COM) of the Ca atoms of residues 338 to 342 (COM344-loop).
In addition, we set a restraining potential with an energy constant Kappa of
100 that starts acting when the 344-loop inserts deep into the membrane (z value of
COM344-loop414Å distance from phosphate atoms) or when the 344-loop reaches
too far into the intracellular water side (z value of COM344-loop 420Å distance
from phosphate atoms). The metadynamics parameters were set to a Gaussian hill
height of 2 kcalmol 1 with a spread of 0.2 Å for the z coordinate. The deposition
rate was one hill every 2 ps and a well-tempered bias factor of 15. A summary of all
biased simulations is found in Table 1.
Preparation of ROS membranes. The ROS membranes were prepared from
frozen bovine retina obtained from W.L. Lawson Company (USA). The bovines
from which the retinas were obtained were slaughtered under guidelines set forth
by the Humane Slaughter Act (US Public Law 85-765) and were approved for
laboratory use by the State Ofﬁce for Health and Social Affairs (LAGeSo Berlin).
ROS isolation and rhodopsin phosphorylation using the native rhodopsin kinase
was carried out as previously described14. Brieﬂy, 100 thawed retina were
vigorously shaken with 90ml of cold 45% (weight to volume) sucrose in ROS buffer
(70mM potassium phosphate, 1mM MgCl2, 0.1mM EDTA, pH 7þ 1mM
DTT and 0.5mM PMSF), and the suspension was then centrifuged at 2,500g for
5min. The supernatant was ﬁltered through gauze, diluted slowly 1:1 with
ROS buffer, and centrifuged at 6,000g for 7min. The pellets were gently
resuspended in 25.5% sucrose (r¼ 1.105 gml 1) and then layered onto four
gradients of composed of 14ml 32.25% sucrose (r¼ 1.135 gml 1) overlaid with
14ml of 27.125% sucrose (r¼ 1.115 gml 1). The gradients were centrifuged
in a swinging bucket rotor at 83,000g (average centrifugal force) for 30min.
ROS were collected from the interface between the 27.12 and 32.25% solutions,
diluted 1:1 with ROS buffer and pelleted by centrifugation (48,000g, 30min). All
the above-described steps were performed under dim red light. For rhodopsin
phosphorylation, ROS were gently homogenized in the dark using an all-glass
douncer in 100mM potassium phosphate pH 7.4 (100ml), and 8mM ATP and
3mM MgCl2 was added. Sealed transparent tubes of this suspension were placed
on a rocking platform under a standard desk lamp at room temperature. After 2 h,
50mM hydroxylamine was added to convert all light-activated rhodopsin species
to opsin. ROS were then washed three to ﬁve times by collecting the membranes by
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centrifugation followed by resuspension in a generous volume of phosphate buffer.
Washed membrane pellets were resuspended in a small volume of 50mM
HEPES pH 7, aliquoted, snap frozen in liquid nitrogen and stored at  80 C.
Phosphorylated opsin was regenerated to phosphorylated rhodopsin by the
addition of a 3-fold molar excess of 11-cis-retinal, which was prepared in-house
using HPLC48. Regeneration was terminated by the addition of 20mM o-tert-
butyl-hydroxylamine49, and rhodopsin concentration was determined by the loss of
500 nm-absorbance (e¼ 0.0408mM 1 cm 1) after bleaching in the presence of
100mM hydroxylamine. Receptor phosphorylation level was evaluated by the
‘Extra Meta II’ assay, which measures the ability of arrestin to stabilize light-
activated rhodopsin as Meta II (refs 14,50). In brief, ROS membranes containing
regenerated phosphorylated rhodopsin were light-activated with a short ﬂash
(4500 nm) under conditions (pH 8, 2 C) favouring Meta I (lmax: 480 nm), the
precursor photoproduct of Meta II (lmax: 380 nm). Receptor binding by arrestin
and stabilization of Meta II manifests as an increase in absorbance at 380 nm.
Analysis indicated that 495% of receptors in our preparations were sufﬁciently
phosphorylated to bind arrestin.
ROS membranes were enriched with commercially available fatty acids.
2-(3-Carboxypropyl)-4,4-dimethyl-2-tridecyl-3-oxazolidinyloxy (5-doxyl-stearic
acid), methyl palmitate and stearic acid were purchased from Sigma-Aldrich, and
4-Palmitamido-2,2,6,6-tetramethylpiperidine-1-oxyl (N-tempoyl palmitamide)
was purchased from Avanti Polar Lipids. Fatty acids were dissolved in ethanol to
yield a stock concentration of 10mM. ROS membranes containing phosphorylated
rhodopsin (ROS-P) were diluted to 5 mM inB2ml of 50mM HEPES buffer pH 7.
Small aliquots of the fatty acid stocks were added to the ROS-P membranes
incrementally, 2 ml every 2min at 30 C, followed by a 1 h incubation at 30 C with
gentle mixing. This protocol is based on that originally reported by Watts et al.51
and was optimized by us to favour membrane insertion of fatty acids and avoid
micelle formation. Fatty acids were added to a ﬁnal concentration of 250 mM.
As a control, ROS-P membranes were treated the same with a stock of pure ethanol
(2.5% ﬁnal ethanol concentration).
Preparation of arrestin mutants. Single cysteine mutations were introduced
into a recombinant bovine arrestin-1 construct that lacks native cysteine and
tryptophan residues (C63A, C128S, C143A, W194F), which is cloned into the
pET15b vector for bacterial expression (Supplementary Note 4). Mutations were
created using PCR and primers obtained from Sigma-Aldrich (Supplementary
Table 3) and veriﬁed by sequencing (LGC genomics). The mutants used in this
study were I72C, M75C, V94C, V139C, V159C, E161C, K163C, F197C, S229C,
T230C, S251C, N271C, T334C, L339C, L342C and S344C. Plasmid DNA was
expressed in Escherichia coli XL1-Blue supercompetant cells (Stratagene 200518)
and isolated using miniprep kits (ThermoFisher Scientiﬁc). For protein expression,
E.coli BL21 (DE3) competent cells (New England BioLabs) were transformed with
plasmid DNA and plated on selective medium containing ampicillin. A single
colony was used to inoculate 5ml LB plus ampicillin (100 mgml 1). After 8 h
incubation at 28 C with shaking, 1ml of this starter culture was used to inoculate
150ml LB plus ampicillin. This culture was grown overnight at 28 C with shaking
and then split between four ﬂasks each containing 2 litres LB plus ampicillin. The
cells were induced with 30 mM IPTG once the optical density at 600 nm reached
0.6. The cells were allowed to grow 416 h at 28 C before collecting by
centrifugation (5,000g 15min). The cells were resuspended in cold lysis buffer
(10mM Tris-HCl, 2mM EDTA, 100mM NaCl pH 7.5þ 5mM DTT) and then
lysed using a microﬂuidizer (Microﬂuidics) in the presence of DNAse. The lysate
was centrifuged (27,000g, 30min), and ammonium sulfate was added to the
supernatant to a concentration of 0.32 gml 1. The precipitated protein was
collected by centrifugation (27,000g, 30min) and then resuspended in 10mM
Tris-HCl, 2mM EDTA pH 7.0þ 5mM DTT. After another centrifugation step to
remove insoluble protein, the lysate was ﬁltered through a 0.8 mm cellulose ﬁlter
and loaded onto 3 5ml HiTrap heparin columns (GE Healthcare), while diluting
1:3 with 10mM Tris-HCl, 2mM EDTA, 100mM NaCl pH 7þ 5mM DTT. After
loading, the column was washed with the same buffer, and arrestin was eluted with
a NaCl gradient (0.1 –0.5M). Arrestin-containing fractions were determined by
SDS–PAGE, pooled, ﬁltered (0.22 mm) and 5mM DTT was added. This protein was
then loaded onto a 5ml HiTrap SP column coupled to a HiTrap Q column
(GE Healthcare) while diluting 1:10 with 10mM Tris-HCl, 2mM EDTA pH
8.5þ 5mM DTT. After loading, the SP column was removed, and the Q column
was washed with pH 8.5 buffer, and arrestin was eluted with a two-step NaCl
gradient, 0–0.1M and 0.1–0.5M. The arrestin-containing fractions were again
determined by SDS PAGE, pooled, concentrated, and buffer exchanged against
50mM HEPES, 130mM NaCl pH 7. Protein concentration was determined by
absorbance at 280 nm (e¼ 0.02076 mM 1 cm 1). Aliquots of puriﬁed protein were
snap frozen in liquid nitrogen and stored at  80 C.
For ﬂuorescent labelling, the puriﬁed arrestin was thawed and diluted to
20 to 50mM in 50mM HEPES, 130mM NaCl pH 7. An B100mM stock of
monobromobimane (ThermoFisher Scientiﬁc) was prepared in dimethyl sulfoxide,
and the concentration was determined by the absorbance at 380 nm
(e¼ 0.005mM 1 cm 1, 1:1,000 dilution of stock in ethanol). Monobromobimane
was added to arrestin at 1:50 molar excess and incubated in the dark at room
temperature. After 1 h, an additional 50-fold molar excess of ﬂuorophore was
added, and labelling proceeded for an additional 2 h. Free label was removed by
washing using centrifugal ﬁlter devices (Amicon Ultra-0.5), followed by size
exclusion chromatography using microcolumns prepared with Sephadex
G15 (Sigma). Concentration and labelling efﬁciency was determined by absorbance
(using extinction coefﬁcients described above). Note that bimane contributes
absorbance at 280 nm roughly equal to its absorbance at 380 nm, and this value
must be subtracted from the protein absorbance peak before calculating the
arrestin concentration.
Centrifugal pull-down analysis. The ability of each bimane-labelled arrestin
mutant to bind phosphorylated rhodopsin in the dark state (pre-complex) and
following light activation (high-afﬁnity complex) was evaluated using a centrifugal
pull-down assay. Brieﬂy, 1 mM bimane-labelled arrestin mutant was mixed with
ROS membranes containing phosphorylated rhodopsin (4 mM; 100 ml volume,
50mM HEPES pH 7). The samples were either kept in the dark or light-activated
(4495 nm) for 15 s, followed by centrifugation at 16,000g for 10min. The super-
natant was removed, and the pellets were solubilized in loading buffer containing
2% SDS and subjected to SDS–PAGE. Bands were visualized using Coomassie
Brilliant Blue. Binding to ROS membranes enriched with the different fatty acids
was analysed alongside ROS membranes lacking fatty acids (Supplementary Fig. 4).
Fluorescence spectroscopy. Steady-state ﬂuorescence was measured using
a SPEX Fluorolog (1680) instrument in front-face mode. The samples were
excited at 400 nm, and emission was collected at 420–600 nm (2 nm step size,
0.5 s integration per point). Excitation slits were narrowed to 0.3mm to minimize
light-activation of the rhodopsin, and emission slits were widened to 4mm.
Samples generally contained 1 mM labelled arrestin and fatty-acid-enriched
ROS containing 4 mM phosphorylated rhodopsin (50mM HEPES pH 7.0, 20 C),
and the spectra were measured in the dark state and following light activation. The
samples were light-activated for 10 s using a 150W ﬁbre optic light source ﬁltered
through a heat ﬁlter (Schott KG2) and a 4495 nm long-pass ﬁlter. The integrated
ﬂuorescence intensity of each spectrum was calculated using the programme Sigma
Plot 13.0 after subtracting appropriate background spectra. For each mutant,
ﬂuorescence spectra in the presence of ROS were normalized to the spectrum of
1 mM unbound arrestin, such that the maximal intensity was equal to 1 (Fig. 4 and
Table 2). Quenching efﬁciencies were calculated by comparing the ﬂuorescence
intensity in the presence of the nitroxide-labelled fatty acids to the ﬂuorescence
with the corresponding unlabelled fatty acid (see Supplementary Table 1).
Data availability. The authors declare that data supporting the ﬁndings of
this study are available within the paper and its Supplementary Information
ﬁles and from the corresponding authors (M.E.S. and J.S.) upon reasonable
request. The following PDB accession codes were used in this work
(1CF1, 4J2Q, 4ZWJ).
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